...
首页> 外文期刊>Nature Genetics >Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations
【24h】

Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations

机译:弥漫性桥脑神经胶质瘤的基因组分析确定了三个分子亚组和反复激活的ACVR1突变

获取原文
获取原文并翻译 | 示例
           

摘要

Diffuse intrinsic pontine glioma (DIPG) is a fatal brain cancer that arises in the brainstem of children, with no effective treatment and near 100% fatality. The failure of most therapies can be attributed to the delicate location of these tumors and to the selection of therapies on the basis of assumptions that DIPGs are molecularly similar to adult disease. Recent studies have unraveled the unique genetic makeup of this brain cancer, with nearly 80% found to harbor a p.Lys27Met histone H3.3 or p.Lys27Met histone H3.1 alteration. However, DIPGs are still thought of as one disease, with limited understanding of the genetic drivers of these tumors. To understand what drives DIPGs, we integrated whole-genome sequencing with methylation, expression and copy number profiling, discovering that DIPGs comprise three molecularly distinct subgroups (H3-K27M, silent and MYCN) and uncovering a new recurrent activating mutation affecting the activin receptor gene ACVR1 in 20% of DIPGs. Mutations in ACVR1 were constitutively activating, leading to SMAD phosphorylation and increased expression of the downstream activin signaling targets ID1 and ID2. Our results highlight distinct molecular subgroups and novel therapeutic targets for this incurable pediatric cancer.
机译:弥漫性桥脑神经胶质瘤(DIPG)是一种致命的脑癌,多发于儿童脑干,没有有效的治疗方法,死亡率接近100%。多数疗法的失败可归因于这些肿瘤的脆弱位置,以及基于DIPG与成人疾病在分子上相似的假设的疗法选择。最近的研究揭示了这种脑癌的独特遗传结构,发现近80%的人携带p.Lys27Met组蛋白H3.3或p.Lys27Met组蛋白H3.1变异。但是,DIPG仍被认为是一种疾病,对这些肿瘤的遗传驱动因素了解有限。为了了解驱动DIPG的因素,我们将全基因组测序与甲基化,表达和拷贝数分析相结合,发现DIPG包含三个分子上不同的亚组(H3-K27M,沉默和MYCN),并发现了影响激活素受体基因的新的经常性激活突变。在20%的DIPG中使用ACVR1。 ACVR1中的突变被组成性激活,导致SMAD磷酸化并增加下游激活素信号传导靶标ID1和ID2的表达。我们的结果突出了这种不可治愈的儿童癌症的独特分子亚组和新型治疗靶标。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号